Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy
Breast cancer cells with the CD44+/CD24− phenotype have been associated with stem cell properties. To analyze effects of cytotoxic chemotherapy on these cells, we examined a series of 50 breast carcinomas before and after neoadjuvant chemotherapy with epirubicin/cyclophosphamide using double immunof...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2010
|
| In: |
Human pathology
Year: 2010, Volume: 41, Issue: 4, Pages: 574-581 |
| ISSN: | 1532-8392 |
| DOI: | 10.1016/j.humpath.2009.08.023 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.humpath.2009.08.023 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0046817709003608 
|
| Author Notes: | Sebastian Aulmann, Nina Waldburger, Roland Penzel, Mindaugas Andrulis, Peter Schirmacher, Hans Peter Sinn |
| Summary: | Breast cancer cells with the CD44+/CD24− phenotype have been associated with stem cell properties. To analyze effects of cytotoxic chemotherapy on these cells, we examined a series of 50 breast carcinomas before and after neoadjuvant chemotherapy with epirubicin/cyclophosphamide using double immunofluorescence. Before treatment, an average of 4.4% of the tumor cells displayed a CD44+/CD24− phenotype. However, after chemotherapy, the frequency of CD44+/CD24− cells dropped to 2% (P = .008). To test this unexpected finding, we analyzed a second collective of 16 patients that preoperatively had received either 4 cycles of doxorubicin/pemetrexed, followed by 4 cycles of docetaxel or 4 cycles of doxorubicin/cyclophosphamide, followed by 4 cycles of docetaxel with similar results (8.7% CD44+/CD24− cells on average before and 1.1% after chemotherapy). In addition, no association was observed between the frequency of CD44+/CD24− cells and the response to chemotherapy or patient survival. However, patients with tumors containing high numbers of CD44+/CD24− cells more frequently developed bone metastases in the course of disease. In conclusion, our findings challenge the proposed role of CD44+/CD24− cells as cancer stem cells in tumor resistance to chemotherapy as they apparently are not selected by conventional cytotoxic agents. |
|---|---|
| Item Description: | Online verfügbar 11 Dezember 2009 Im Titel sind die Zeichen + und - hochgestellt Gesehen am 28.11.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1532-8392 |
| DOI: | 10.1016/j.humpath.2009.08.023 |